Navigation Links
Combo PET/CT Scan Helps Spot Breast Cancer's Spread
Date:11/27/2007

Technique helps detect metastases earlier for women with inflammatory breast cancer, study finds

TUESDAY, Nov. 27 (HealthDay News) -- A technique that combines a PET scan with a CT scan can help spot the spread of inflammatory breast cancer, a rare but very aggressive form of the disease, researchers report.

"It is a quicker way of assessing everything," said lead researcher Dr. Selin Carkaci, assistant professor of radiology at The University of Texas M.D. Anderson Cancer Center in Houston. "Our results show it is very useful," she said.

Carkaci was expected to present her findings Monday at the annual meeting of the Radiological Society of North America, in Chicago.

According to the American Cancer Society, IBC accounts for 1 percent to 5 percent of all breast cancer cases in the United States. Often by the time it is discovered, it has spread. The five-year survival rate for those with IBC is 25 percent to 50 percent, according to the cancer society.

The new combo technology has been used in recent years for assessing other cancers as well, Carkaci noted. While the separate technologies of PET (positron emission tomography) and CT (computed tomography) have been in use since the early 1970s, their combined use came into practice only about eight years ago. Patients being treated at cancer centers across the United States should have access to this test, which is becoming more common, Carkaci said.

The technique she used is called FDG-PET/CT -- for "F-18 fluorodeoxyglucose positron emission tomography and computed tomography".

In a PET scan, a small amount of the radioactive drug F-18-labeled glucose is injected into the body. Fast-growing cancer cells feed on sugars and absorb it more quickly than do normal cells, Carkaci explained, so they "light up" on the images created by the PET scanner.

On the other hand, "the CT scanner takes a series of X-ray pictures, which are combined by a computer to create an extremely detailed image of the internal organs or other parts of the body," she said.

The scan gives great anatomical detail including the size, shape and location of the tumor. Together, the tests provide the most complete data on the tumor and its spread, Carkaci said.

In the study, doctors scanned 41 women newly diagnosed with inflammatory breast cancer. They found metastases in 20 patients, or 49 percent. They used biopsy or additional imaging to confirm the results when possible. Biopsy confirmation of metastases were available in four of 13 patients and additional imaging confirmation in nine.

"We found that FDG-PET/CT is 95 percent accurate in identifying distant metastases and 98 percent accurate in identifying regional lymph node metastases," Carkaci said.

"This [scanning] is done immediately after diagnosis, and then following the chemotherapy, to evaluate the response to treatment," she said.

The hope is to stop the cancer in its tracks.

One co-author, Dr. Homer Macapinlac, chair and professor of nuclear medicine at M.D. Anderson, reported being a consultant for General Electric Company and Siemens AG. Both companies produce scanners.

The study findings are "significant for the high rate of metastatic disease, with almost one half of the women with PET/CT able to identify the tumors at an early stage," said Dr. David Bluemke, professor of radiology and medicine and clinical director, MRI, Johns Hopkins Medical Institution, Baltimore.

"The data is very compelling for routine and early use of PET/CT for patients with inflammatory breast cancer," he said. "Although the study was small, the high accuracy rate appears promising for patients with this condition."

More information

To learn more about inflammatory breast cancer, visit the U.S. National Cancer Institute.



SOURCES: David Bluemke, M.D., Ph.D., professor, radiology and medicine, and clinical director MRI, Johns Hopkins Medical Institutions, Baltimore; Selin Carkaci, M.D., assistant professor, diagnostic radiology, University of Texas M.D. Anderson Cancer Center, Houston; Nov. 27, 2007, presentation, annual meeting of the Radiological Society of North America, Chicago


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Radiation and drug combo helps boost efficacy of lung cancer treatment
2. Aerobic, Weight Training Combo Best Against Diabetes
3. New antibiotic drug combo to speed up treatment of tuberculosis
4. Drug Combo Helps Fight Marfan Syndrome
5. Drug Combo Blocks Pain Without Impairing Movement
6. Two-Drug Combo Fights Brain Tumors
7. CPR, Defibrillator Combo Boosts Cardiac Incident Survival
8. Drug Combo Boosts Multiple Myeloma Survival
9. Drug Combos Effective Against Rheumatoid Arthritis
10. 18F-DG PET/CT can highly increase the detection of colorectal cancer
11. PET/CT Brings New Hope to Patients With Deadly Form of Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Combo PET/CT  Scan Helps Spot Breast Cancer's Spread
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... its new partnership with the Home Care Association of America (HCAOA). This agreement ... Private Duty Accreditation services, as well as discounts on Accreditation University (AU) educational ...
(Date:4/28/2017)... ... , ... Beginning in 2017, Ridgecrest Herbals will be phasing out the homeopathic ... Extra Strength formula. To ensure that the effectiveness of Clear Lungs Extra Strength is ... , Removal of the homeopathic element , Adding their patented ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. ... GlycoMark test throughout the Northeast U.S. , GlycoMark is the only clinically ... GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic excursions, ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
(Date:4/28/2017)... ... , ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical ... Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord ... donate. , “Women’s Hospital at Renaissance has been a collection partner for the ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
Breaking Medicine Technology: